These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2094 related articles for article (PubMed ID: 20399149)

  • 21. The Cancer Genome Atlas expression profiles of low-grade gliomas.
    Gonda DD; Cheung VJ; Muller KA; Goyal A; Carter BS; Chen CC
    Neurosurg Focus; 2014 Apr; 36(4):E23. PubMed ID: 24812719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation.
    Liu F; Cox CD; Chowdhury R; Dovek L; Nguyen H; Li T; Li S; Ozer B; Chou A; Nguyen N; Wei B; Antonios J; Soto H; Kornblum H; Liau L; Prins R; Nghiemphu PL; Yong W; Cloughesy T; Lai A
    J Neurooncol; 2019 May; 142(3):423-434. PubMed ID: 30838489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
    Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
    Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications.
    Malta TM; de Souza CF; Sabedot TS; Silva TC; Mosella MS; Kalkanis SN; Snyder J; Castro AVB; Noushmehr H
    Neuro Oncol; 2018 Apr; 20(5):608-620. PubMed ID: 29036500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel prognostic six-CpG signature in glioblastomas.
    Yin AA; Lu N; Etcheverry A; Aubry M; Barnholtz-Sloan J; Zhang LH; Mosser J; Zhang W; Zhang X; Liu YH; He YL
    CNS Neurosci Ther; 2018 Mar; 24(3):167-177. PubMed ID: 29350455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome.
    Kelly AD; Kroeger H; Yamazaki J; Taby R; Neumann F; Yu S; Lee JT; Patel B; Li Y; He R; Liang S; Lu Y; Cesaroni M; Pierce SA; Kornblau SM; Bueso-Ramos CE; Ravandi F; Kantarjian HM; Jelinek J; Issa JP
    Leukemia; 2017 Oct; 31(10):2011-2019. PubMed ID: 28074068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.
    Laffaire J; Everhard S; Idbaih A; Crinière E; Marie Y; de Reyniès A; Schiappa R; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Thillet J; Ducray F
    Neuro Oncol; 2011 Jan; 13(1):84-98. PubMed ID: 20926426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deciphering the etiology and role in oncogenic transformation of the CpG island methylator phenotype: a pan-cancer analysis.
    Yates J; Boeva V
    Brief Bioinform; 2022 Mar; 23(2):. PubMed ID: 35134107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of DNA methylation in adult diffuse gliomas.
    Aoki K; Natsume A
    Brain Tumor Pathol; 2019 Apr; 36(2):84-91. PubMed ID: 30937703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors.
    Schenkel LC; Mathew J; Hirte H; Provias J; Paré G; Chong M; Grafodatskaya D; McCready E
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The CpG island methylator phenotype: what's in a name?
    Hughes LA; Melotte V; de Schrijver J; de Maat M; Smit VT; Bovée JV; French PJ; van den Brandt PA; Schouten LJ; de Meyer T; van Criekinge W; Ahuja N; Herman JG; Weijenberg MP; van Engeland M
    Cancer Res; 2013 Oct; 73(19):5858-68. PubMed ID: 23801749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MethylMeter(®): bisulfite-free quantitative and sensitive DNA methylation profiling and mutation detection in FFPE samples.
    McCarthy D; Pulverer W; Weinhaeusel A; Diago OR; Hogan DJ; Ostertag D; Hanna MM
    Epigenomics; 2016 Jun; 8(6):747-65. PubMed ID: 27337298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA demethylation is associated with malignant progression of lower-grade gliomas.
    Nomura M; Saito K; Aihara K; Nagae G; Yamamoto S; Tatsuno K; Ueda H; Fukuda S; Umeda T; Tanaka S; Takayanagi S; Otani R; Nejo T; Hana T; Takahashi S; Kitagawa Y; Omata M; Higuchi F; Nakamura T; Muragaki Y; Narita Y; Nagane M; Nishikawa R; Ueki K; Saito N; Aburatani H; Mukasa A
    Sci Rep; 2019 Feb; 9(1):1903. PubMed ID: 30760837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
    Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
    Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. G-cimp status prediction of glioblastoma samples using mRNA expression data.
    Baysan M; Bozdag S; Cam MC; Kotliarova S; Ahn S; Walling J; Killian JK; Stevenson H; Meltzer P; Fine HA
    PLoS One; 2012; 7(11):e47839. PubMed ID: 23139755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SOCS3 promoter hypermethylation is a favorable prognosticator and a novel indicator for G-CIMP-positive GBM patients.
    Feng Y; Wang Z; Bao Z; Yan W; You G; Wang Y; Hu H; Zhang W; Zhang Q; Jiang T
    PLoS One; 2014; 9(3):e91829. PubMed ID: 24633048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA methylation in adult diffuse gliomas.
    LeBlanc VG; Marra MA
    Brief Funct Genomics; 2016 Nov; 15(6):491-500. PubMed ID: 27288434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
    Pratt D; Dominah G; Lobel G; Obungu A; Lynes J; Sanchez V; Adamstein N; Wang X; Edwards NA; Wu T; Maric D; Giles AJ; Gilbert MR; Quezado M; Nduom EK
    Neurosurgery; 2019 Aug; 85(2):280-289. PubMed ID: 30011045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular and cellular heterogeneity: the hallmark of glioblastoma.
    Aum DJ; Kim DH; Beaumont TL; Leuthardt EC; Dunn GP; Kim AH
    Neurosurg Focus; 2014 Dec; 37(6):E11. PubMed ID: 25434380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A five-CpG signature of microRNA methylation in non-G-CIMP glioblastoma.
    Kang EM; Yin AA; He YL; Chen WJ; Etcheverry A; Aubry M; Barnholtz-Sloan J; Mosser J; Zhang W; Zhang X
    CNS Neurosci Ther; 2019 Sep; 25(9):937-950. PubMed ID: 31016891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 105.